Syndax Pharmaceuticals | ARS: Annual Report to Security Holders
Syndax Pharmaceuticals | DEF 14A: Definitive information statements
Syndax Pharmaceuticals | DEFA14A: Others
Syndax Pharmaceuticals | 8-K: Current report
Syndax Pharmaceuticals | 10-K: Annual report
Syndax Pharmaceuticals | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Syndax Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Syndax Pharmaceuticals | 8-K: Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Kynam Capital Management, LP(6.67%),Kynam Capital Management GP, LLC(6.67%), etc.
Syndax Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Point72 Asset Management, L.P.(3.3%),Point72 Capital Advisors, Inc.(3.3%), etc.
Syndax Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Avidity Partners Management LP(4.7%),Avidity Partners Management (GP) LLC(4.7%), etc.
Syndax Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-The Vanguard Group(5.11%)
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Metzger Michael A
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Goldan Keith A.
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gallagher Neil
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Legault Pierre
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Podlesak Dennis
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Morrison Briggs
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Meury William
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Katkin Keith
No Data